Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India
Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India
复制标题
DOI：
10.1093/tropej/fmn080
复制
发表时间：
2009-06-01
影响因子：
2
通讯作者：
Solomon, Suniti
中科院分区：
文献类型：
--
作者：
Kumarasamy, N.;Venkatesh, Kartik K.;Solomon, Suniti
在资源有限的环境中，感染艾滋病毒的儿童越来越多地获得高效抗逆转录病毒治疗（HAART），但有记录的纵向数据仍然有限。我们的目的是研究67名南印度艾滋病毒感染儿童的临床和免疫学结果，在三级艾滋病毒护理计划中进行了18个月的HAART随访。入组时中位CD4细胞计数为290个细胞1(1)，治疗开始时为225个细胞1(1)。从治疗开始到治疗6个月后，患者的CD4细胞计数显著上升（701个细胞1）；P 0.007)， 12个月（741个细胞1）；P 0.037)，治疗18个月(718个细胞1 (1)；p 0.005)。治疗中最常见的不良事件是恶心（20.9）和皮疹（25.4）。超过五分之一的患者（25.4）由于毒性而替代治疗，19.4的患者改用二线含蛋白酶抑制剂方案。在这个南印度儿科队列中，非专利HAART是安全、有效且耐受性相对较好的。
HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with 18 months of follow-up on HAART at a tertiary HIV care program. The median CD4 cell count at enrolment was 290 cells l(1) and at treatment initiation was 225 cells l(1). Patients demonstrated a significant rise in their CD4 cell counts between treatment initiation and after 6 months (701 cells l(1); p 0.007), 12 months (741 cells l(1); p 0.037), and 18 months of therapy (718 cells l(1); p 0.005). The most common adverse events to therapy were nausea (20.9) and rash (25.4). Over one-fifth of patients (25.4) substituted therapy due to toxicities and 19.4 of patients switched to second-line protease inhibitor-containing regimens. In this South Indian pediatric cohort, generic HAART was safe, effective and relatively well tolerated.